不稳定性冠状动脉病患者CD62P,CD63含量的变化  

Changes of the CD62P and CD63 in unstable coronary artery disease

作　　者：吴红玲 王晓艳 苏卓娃 向前 杜冀辉 庞红 方红城 

机构地区：[1]深圳市南山人民医院心内科,广东省深圳市518052 [2]深圳市南山人民医院中心实验室,广东省深圳市518052

出　　处：《中国临床康复》2003年第9期1474-1475,共2页Chinese Journal of Clinical Rehabilitation

摘　　要：目的检测血小板膜表面CD62P,CD63的含量,研究不稳定性冠状动脉病(UCAD)患者血小板活化程度,探讨UCAD检测的新途径。方法病例来源于2001-10/2002-12在我院心血管门诊和心内科住院的65例UCAD患者。其中不稳定性心绞痛(A组)50例;非Q波性心肌梗死(NQMI,B组)15例。正常健康对照组(C组)59例。入选者性别、年龄大致相同。采用全血法流式细胞术(flowcytometry,FCM)分别测定U-CAD中UA、NQMI组和正常对照组患者血小板膜活化CD62P、CD63的含量。各组数据均用均数±标准(x珔±s)表示。成组设计的两样本比较采用u检验。结果65例UCAD中A组患者CD62P,CD63含量分别为21.92±18.74和3.49±3.19;B组含量分别为21.24±13.36和3.76±2.20;C组的含量分别为4.16±1.59和1.64±0.82。A组、B组分别与C组比较,P<0.001,差异有非常显著性意义,两组血小板膜上CD62P,CD63水平均显著高于正常对照组。A、B两组之间CD62P、CD63含量比较差异无显著性(P>0.5)。结论UCAD患者中不论是A组、还是B组均存在血小板活性增高。采用FCM检测CD62P、CD63可为临床上评价UCAD患者血小板活化程度的高低提供早期、特异诊断指标,亦可能是对UCAD疾病诊断、治疗方案选择、预后判断检测的一种新途径。Aim Measuring CD62P,CD63 on the surface of the platelets,to study the extent of the platelet activation status in UCADs, to explore the new method checking the UCAD.Method All the 65 UCAD patients were from outpatient and in patient cardiac departments between 2001,10 to 2002,12.50/65 of the patients was UA,15/65 was NQMI. 59 Normal control people were chosen in this study, and there was no statistic difference at the age and the sex.Measured respectively the CD62 and CD63 on the surface of the platelets among the UA, NQMI and healthy comparison groups by the whole blood flow cytometry(FCM) method. All the data was mean± standard deviation(± s). Result In the 65 UCADs , the CD62P and the CD63 were 21.92± 18.7and 3.49± 3.19 in UA group, 21.24± 13.36 and 3.76± 2.20 in NQMI group, 4.16± 1.95 and 1.64± 0.82 in healthy group .UA group and NQMI group were distinctive difference compared to healthy group respectively ,P< 0.001.Both of CD62P and the CD63 in the UA group and the NQMI group were distinctly high than the healthy comparison group. There was no statistic difference between the UA and NQMI groups( P >0.05) . Conclusion In the UCMI cases, the platelet activation state was heightened no matter in UAs or in NQMIs. In the clinic , it perhaps offer early special diagnostic guideline to evaluating the platelet activation extent by measuring the CD62P,CD63 through the FCM, and it may be a new measuring method for diagnose, treating scheme and estimating prognosis to UCAD.<P>

关 键 词：不稳定性冠状动脉病 CD62P CD63 含量检测 血小板活化程度 不稳定性心绞痛 非Q波性心肌梗死 

分 类 号：R541.4[医药卫生—心血管疾病] R542.22[医药卫生—内科学]